Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Harvard University Press · Massachusetts General Hospital
Abstract
Targeted therapy against the BRAF/mitogen-activated protein kinase (MAPK) pathway is a promising new therapeutic approach for the treatment of melanoma. Treatment with selective BRAF inhibitors results in a high initial response rate but limited duration of response. To counter this, investigators propose combining this therapy with other targeted agents, addressing the issue of redundancy and signaling through different oncogenic pathways. An alternative approach is combining BRAF/MAPK-targeted agents with immunotherapy. Preliminary evidence suggests that oncogenic BRAF (BRAF(V600E)) contributes to immune escape and that blocking its activity via MAPK pathway inhibition leads to increased expression of…
Citation impact
- FWCI
- 26.27
- Percentile
- 100%
- References
- 22
Authors
12- ABAndrea BoniCorresponding
Harvard University Press, Massachusetts General Hospital
- APAlexandria P. Cogdill
Harvard University Press, Massachusetts General Hospital
- PDPing Dang
Harvard University Press, Massachusetts General Hospital
- DUDurga Udayakumar
Harvard University Press, Massachusetts General Hospital
- CJChing-Ni Jenny Njauw
Harvard University Press, Massachusetts General Hospital
Topics & keywords
- Melanoma
- MAPK/ERK pathway
- Cancer research
- Immunotherapy
- MEK inhibitor
- Immune system
- Targeted therapy
- Biology
- Good health and well-being